SC
RARE icon

Steven Cohen’s Ultragenyx Pharmaceutical RARE Stock Holding History

Steven Cohen’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-58,800
Closed -$2.42M – 2274
2024
Q2 		$2.42M Buy
+58,800
New +$2.51M 0.01% 1043

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Steven Cohen's RARE Position: Q2 2026 in Review

Steven Cohen sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 893,295 shares — an estimated $18.7M sold.

Steven Cohen first reported a position in RARE in Q1 2017 and held it in 31 quarters. The position peaked at $67.4M in Q2 2021. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Steven Cohen reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 893,295 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $18.7M.
  • Steven Cohen first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and held it in 31 quarters.
  • Steven Cohen's Ultragenyx Pharmaceutical position peaked at $67.4M in Q2 2021.
  • 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.